Simple blood test may provide early detection of cancer

NewsGuard 100/100 Score

90 percent detection rate in clinical tests for multiple types of cancers

A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer.

Prof. Kapelushnik of BGU's Faculty of Health Sciences and his team developed a device that illuminates cancer cells with less than a teaspoon of blood. The test uses infrared light to detect miniscule changes in the blood of a person who has a cancerous growth somewhere, even before the disease has spread. Various molecules released into the bloodstream cause it to absorb infrared light slightly differently compared to that of healthy people.

In the latest clinical trial with 200 patients and a control group, the test identified specific cancers in 90 percent of the patients and found other types of cancer, as well. The researchers are focused on detection of common cancers, such as lung and ovarian cancer.

Doctors believe that it is critical to increase cancer detection in early stages to prevent the need for long, difficult and costly treatments in more advanced stages.

"This is still research in the early stages of clinical trials," clarifies Prof. Joseph Kapelushnik, who is also head of the Department of Pediatric Hemato-Oncology at Soroka hospital. "But the purpose is to develop an efficient, cheap and simple method to detect as many types of cancers as possible. We want to be able to detect cancer while a patient is still feeling good, before it has a chance to metastasize, meaning fewer treatments, less suffering and many more lives saved."

More clinical trials will be conducted in the next 18 months.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breast cancer survivors at higher risk of developing second cancers